ORAL PEMPHIGUS VULGARIS: A CASE REPORT

구강내 발생한 심상성 천포창 환자의 치험례

  • Kim, Il-Kyu (Department of Oral and Maxillofacial Surgery, Department of Dentistry, College of Medicine, In-Ha University) ;
  • Choi, Jin-Ung (Department of Oral and Maxillofacial Surgery, Department of Dentistry, College of Medicine, In-Ha University) ;
  • Yang, Jung-Eun (Department of Oral and Maxillofacial Surgery, Department of Dentistry, College of Medicine, In-Ha University) ;
  • Jang, Jae-Won (Department of Oral and Maxillofacial Surgery, Department of Dentistry, College of Medicine, In-Ha University) ;
  • Sasikala, Balaraman (Department of Oral and Maxillofacial Surgery, Department of Dentistry, College of Medicine, In-Ha University) ;
  • Kim, Lucia (Department of Oral and Maxillofacial Surgery, Department of Pathology, College of Medicine, In-Ha University)
  • 김일규 (인하대학교 의과대학 치과학교실) ;
  • 최진풍 (인하대학교 의과대학 치과학교실) ;
  • 양정은 (인하대학교 의과대학 치과학교실) ;
  • 장재원 (인하대학교 의과대학 치과학교실) ;
  • 사시카라바라라만 (인하대학교 의과대학 치과학교실) ;
  • 김루시아 (인하대학교 의과대학 병리학교실)
  • Published : 2009.09.30

Abstract

Pemphigus vulgaris is a chronic autoimmune intraepithelial blistering disease with oral mucosal manifestations that very often precede the skin lesions. The vesicles or bullae are produced by an acantholytic process, detachment of differentiating keratinocytes from one another in the epithelial stratum spino sum or spinous cell layer. The pathogenesis of this disease is initially manifested by IgG(mainly) binding to desmosome(desmoglein 3 or 1) in the intercellular spaces of epithelium. This autoantibody binding caused the release of a plasminogen activator(a proteolytic enzyme) from keratinocytes. This ultimately results in cell to cell separation. The mainstay therapy of pemphigus vulgaris is systemic corticosteroids and immunosuppressive agents to eliminate the pathogenic autoantibodies from circulation. A 41-year old woman presented with a 1.5 year history of oral ulceration. There were no lesions on the skin or other mucosal sites. Histology and immunostaining were consistent with pemphigus vulgaris. Control of oral ulceration and normal oral function were achieved after systemic corticosteroids and immunosuppressive agents were instituted.

Keywords

References

  1. Castellano Suarez JL : Gingival disorders of immune origin. Med Oral 7 : 271, 2002
  2. Scully C, Challacombe SJ : Pemphigus vulgaris: Update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 13 : 397, 2002 https://doi.org/10.1177/154411130201300504
  3. Mignogna MD, Lo Muzio L, Bucci E : Clinical features of gingival pemphigus vulgaris. J Clin Periodontol 28 : 489, 2001 https://doi.org/10.1034/j.1600-051x.2001.028005489.x
  4. Robinson NA, Yeo JF, Lee YS et al : Oral pemphigus vulgaris: a case report and literature update. Ann Acad Med Singapore 33 : 63, 2004
  5. Gazit E, Loewenthal R : The immunogenetics of pemphigus vulgaris. Autoimmun Rev 4 : 16, 2005 https://doi.org/10.1016/j.autrev.2004.05.002
  6. Anhalt GJ, Diaz LA : Pemphigus vulgaris-A model for cutaneous autoimmunity. J Am Acad Dermatol 51 : s20 , 2004 https://doi.org/10.1016/j.jaad.2004.01.011
  7. Brenner S, Tur E, Shapiro J et al : Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 40 : 562, 2001 https://doi.org/10.1046/j.1365-4362.2001.01266.x
  8. Campo-Voegeli A, Muniz F, Mascaro JM et al : Neonatal pemphigus vulgaris with extensive mucocutaneous lesions from a mother with oral pemphigus vulgaris. Fr J Dermatol 147 : 801, 2002 https://doi.org/10.1046/j.1365-2133.2002.04969.x
  9. Muhammad JK, Lewis MA, Crean SJ : Oral pemphigus vulgaris occurring during pregnancy. J Oral Pathol Med 31 : 121, 2002 https://doi.org/10.1046/j.0904-2512.2001.00000.x
  10. Femiano F, Gombos F, Scully C : Pemphigus vulgaris with oral involvement: evaluation of two different systemic cortocosteroid therapeutic protocols. JEADV 16 : 353, 2002 https://doi.org/10.1046/j.1468-3083.2002.00461.x
  11. Mazzi G, Raineri A, Zanolli FA et al : Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfusion and Apheresis Science 28 : 13, 2003 https://doi.org/10.1016/S1473-0502(02)00095-2
  12. Bhol KC, Desai A, Kumari S et al : Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 100 : 172, 2001 https://doi.org/10.1006/clim.2001.5061